Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0305 in Relapsed or Refractory Multiple Myeloma (Phase I/II Modular Study)
jRCT2041240003Phase 2Recruiting
- Sponsor
- AstraZeneca
- Start
- Jul 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of AZD0305 in multiple myeloma (MM) (2 arms), sponsored by AstraZeneca. Primary endpoints: Dose-limiting toxicities (DLTs) and Adverse events and serious adverse events. Started Jul 2024; status: recruiting.
02
Drugs
AZD0305
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2041240003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041240003.